These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 7865284)

  • 1. Mucosal immunity in the female genital tract: relevance to vaccination efforts against the human immunodeficiency virus.
    Mestecky J; Kutteh WH; Jackson S
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S11-20. PubMed ID: 7865284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Routes of immunization and antigen delivery systems for optimal mucosal immune responses in humans.
    Mestecky J; Michalek SM; Moldoveanu Z; Russell MW
    Behring Inst Mitt; 1997 Feb; (98):33-43. PubMed ID: 9382757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humoral immune responses to the human immunodeficiency virus type-1 (HIV-1) in the genital tract compared to other mucosal sites.
    Mestecky J
    J Reprod Immunol; 2006 Dec; 72(1-2):1-17. PubMed ID: 17095369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunologic uniqueness of the genital tract: challenge for vaccine development.
    Mestecky J; Moldoveanu Z; Russell MW
    Am J Reprod Immunol; 2005 May; 53(5):208-14. PubMed ID: 15833098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Female genital tract immunity: distinct immunological challenges for vaccine development.
    Naz RK
    J Reprod Immunol; 2012 Jan; 93(1):1-8. PubMed ID: 22154945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New perspectives in vaccine development: mucosal immunity to infections.
    McGhee JR; Kiyono H
    Infect Agents Dis; 1993 Apr; 2(2):55-73. PubMed ID: 8162356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides.
    Jiang JQ; Patrick A; Moss RB; Rosenthal KL
    J Virol; 2005 Jan; 79(1):393-400. PubMed ID: 15596832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Humoral aspects of mucous membrane immunity--perspectives for the female genital tract].
    Briese V
    Zentralbl Gynakol; 1986; 108(21):1282-8. PubMed ID: 3544610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosal vaccination strategies for women.
    Kozlowski PA; Cu-Uvin S; Neutra MR; Flanigan TP
    J Infect Dis; 1999 May; 179 Suppl 3():S493-8. PubMed ID: 10099127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal immunization with inactivated HIV-1-capturing nanospheres induces a significant HIV-1-specific vaginal antibody response in mice.
    Akagi T; Kawamura M; Ueno M; Hiraishi K; Adachi M; Serizawa T; Akashi M; Baba M
    J Med Virol; 2003 Feb; 69(2):163-72. PubMed ID: 12683403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges for vaccination against sexually-transmitted diseases: induction and long-term maintenance of mucosal immune responses in the female genital tract.
    Rosenthal KL; Gallichan WS
    Semin Immunol; 1997 Oct; 9(5):303-14. PubMed ID: 9327525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sublingual immunization with an HIV subunit vaccine induces antibodies and cytotoxic T cells in the mouse female genital tract.
    Hervouet C; Luci C; Cuburu N; Cremel M; Bekri S; Vimeux L; Marañon C; Czerkinsky C; Hosmalin A; Anjuère F
    Vaccine; 2010 Aug; 28(34):5582-90. PubMed ID: 20600505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge.
    Dumais N; Patrick A; Moss RB; Davis HL; Rosenthal KL
    J Infect Dis; 2002 Oct; 186(8):1098-105. PubMed ID: 12355360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B cell and T cell immunity in the female genital tract: potential of distinct mucosal routes of vaccination and role of tissue-associated dendritic cells and natural killer cells.
    Anjuère F; Bekri S; Bihl F; Braud VM; Cuburu N; Czerkinsky C; Hervouet C; Luci C
    Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():117-22. PubMed ID: 22882377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing activity and cellular immune responses induced in mice after immunization with apoptotic HIV-1/murine leukemia virus infected cells.
    Hinkula J; Walther-Jallow L; Laurén A; Mäkitalo B; Oberg M; Wahren B; Fenyö EM; Spetz AL
    Vaccine; 2009 Oct; 27(46):6424-31. PubMed ID: 19549607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucosal immune responses in the genital tract of HIV-1-exposed uninfected women.
    Hirbod T; Broliden K
    J Intern Med; 2007 Jul; 262(1):44-58. PubMed ID: 17598814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In defense of mucosal surfaces. Development of novel vaccines for IgA responses protective at the portals of entry of microbial pathogens.
    McGhee JR; Mestecky J
    Infect Dis Clin North Am; 1990 Jun; 4(2):315-41. PubMed ID: 2189002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucosal immunity, HIV transmission, and AIDS.
    Miller CJ; McGhee JR; Gardner MB
    Lab Invest; 1993 Feb; 68(2):129-45. PubMed ID: 8441249
    [No Abstract]   [Full Text] [Related]  

  • 19. Intranasal immunization of young mice with a multigene HIV-1 vaccine in combination with the N3 adjuvant induces mucosal and systemic immune responses.
    Bråve A; Hallengärd D; Schröder U; Blomberg P; Wahren B; Hinkula J
    Vaccine; 2008 Sep; 26(40):5075-8. PubMed ID: 18450334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploration of mucosal immunity in humans: relevance to vaccine development.
    Czerkinsky C; Holmgren J
    Cell Mol Biol (Noisy-le-grand); 1994; 40 Suppl 1():37-44. PubMed ID: 7950860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.